Samsung Biosimilar Lantus Filings Planned As Pipeline Progresses
This article was originally published in PharmAsia News
Executive Summary
Samsung's biosimilar projects seem to be progressing smoothly, with its affiliate Samsung Bioepis in the final stage of a Phase III global clinical study for SB9, its biosimilar version of Sanofi's blockbuster Lantus (insulin glargine), for which an approval filing is planned in the U.S. in the latter half of this year and in Europe early next year.